Jong-kil Nam
Yangsan, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 12, 2025
Lipocalin 2 as a potential liquid biopsy marker for early detection of bladder cancer.
Journal: Clinical and translational medicine
Published: September 22, 2025
Emerging technologies and clinical translation of urine-based liquid biopsy in urological cancers.
Journal: Genes & genomics
Published: August 05, 2025
Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implications.
Journal: Cancer letters
Published: June 04, 2024
Association between PDCD6-VNTR polymorphism and urinary cancer susceptibility.
Journal: Genes & genomics
Published: April 04, 2024
Exploring the Relationship between CLPTM1L-MS2 Variants and Susceptibility to Bladder Cancer.
Journal: Genes
Published: November 06, 2023
VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer.
Journal: BMC medical genomics
Published: April 16, 2021
Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy.
Journal: International journal of molecular sciences
Published: January 31, 2020
Moxibustion as an adjunct for lower urinary tract symptoms associated with benign prostate enlargement: A randomized controlled pilot trial.
Journal: Medicine
Published: January 25, 2020
Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial.
Journal: BMJ open
Published: December 15, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026